Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PALB2 inact mut |
| Therapy | Rucaparib |
| Indication/Tumor Type | prostate cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 inact mut | prostate cancer | sensitive | Rucaparib | Case Reports/Case Series | Actionable | In a Phase II trial (TRITON2), 2 of 2 patients with metastatic castrate-resistant prostate cancer harboring deleterious PALB2 alterations demonstrated a PSA response after treatment with Rubraca (rucaparib), with one of those patients demonstrating partial radiographic response that was ongoing 3.9 months, and the other a 47% reduction in tumor volume (PMID: 32086346; NCT02952534). | 32086346 |
| PALB2 inact mut | prostate cancer | sensitive | Rucaparib | Guideline | Actionable | Rubraca (rucaparib) is included in guidelines for patients with metastatic castration-resistant prostate cancer harboring PALB2 mutations (PMID: 41679466; ESMO.org). | detail... 41679466 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| ESMO Clinical Practice Guidelines | Full reference... | |
| (32086346) | Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. | Full reference... |
| (41679466) | Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Full reference... |